The Ahmed ClearPath (ACP) glaucoma drainage device provides effective and sustained intraocular pressure (IOP) control in childhood glaucoma over a long-term follow-up, significantly reducing the need for medications while maintaining a strong safety profile, according to a study.
The retrospective review included 19 eyes from 17 pediatric patients who underwent ACP implantation, with an average follow-up period of over 4 years.
There was a significant reduction in IOP, decreasing from an average of 32.2 mm Hg before surgery to 16.1 mm Hg at 4 years postoperatively. The median number of glaucoma medications also dropped from 2.5 to 1 over the same period. The procedure maintained a high success rate, with 79% of cases meeting the defined success criteria at 4 years. The researchers noted that 5 eyes achieved complete success, requiring no glaucoma medications.
There were no vision-threatening complications were reported.
Reference
Elhusseiny AM, Sayed MS, Khodeiry MM, et al. Long-term outcomes of Ahmed ClearPath in childhood glaucoma: four-year results. J AAPOS. 2025;104172. doi: 10.1016/j.jaapos.2025.104172. Epub ahead of print. PMID: 40058564.
Related Content
